These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519 [TBL] [Abstract][Full Text] [Related]
27. Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study. Camponovo F; Ockenhouse CF; Lee C; Penny MA BMC Infect Dis; 2019 Oct; 19(1):920. PubMed ID: 31664924 [TBL] [Abstract][Full Text] [Related]
28. Insecticide-treated nets for preventing malaria. Pryce J; Richardson M; Lengeler C Cochrane Database Syst Rev; 2018 Nov; 11(11):CD000363. PubMed ID: 30398672 [TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets. Seo MK; Baker P; Ngo KN Malar J; 2014 Feb; 13():66. PubMed ID: 24564883 [TBL] [Abstract][Full Text] [Related]
30. Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi. Bell GJ; Loop MS; Mvalo T; Juliano JJ; Mofolo I; Kamthunzi P; Tegha G; Lievens M; Bailey J; Emch M; Hoffman I BMC Public Health; 2020 Jun; 20(1):910. PubMed ID: 32532234 [TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of district-wide seasonal malaria chemoprevention when implemented through routine malaria control programme in Kita, Mali using fixed point distribution. Diawara H; Walker P; Cairns M; Steinhardt LC; Diawara F; Kamate B; Duval L; Sicuri E; Sagara I; Sadou A; Mihigo J; Eckert E; Dicko A; Conteh L Malar J; 2021 Mar; 20(1):128. PubMed ID: 33663488 [TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa. Otieno L; Guerra Mendoza Y; Adjei S; Agbenyega T; Agnandji ST; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kariuki S; Kremsner P; Lanaspa M; Lell B; Lievens M; Lusingu J; Malabeja A; Masoud NS; Mtoro AT; Njuguna P; Ofori-Anyinam O; Otieno GA; Otieno W; Owusu-Agyei S; Schuerman L; Sorgho H; Tanner M; Tinto H; Valea I; Vandoolaeghe P; Sacarlal J; Oneko M Vaccine; 2020 Jan; 38(4):897-906. PubMed ID: 31708182 [TBL] [Abstract][Full Text] [Related]
33. Potential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling study. Sauboin CJ; Van Bellinghen LA; Van De Velde N; Van Vlaenderen I Malar J; 2015 Dec; 14():524. PubMed ID: 26702637 [TBL] [Abstract][Full Text] [Related]
34. Simulated impact of RTS,S/AS01 vaccination programs in the context of changing malaria transmission. Brooks A; Briët OJ; Hardy D; Steketee R; Smith TA PLoS One; 2012; 7(3):e32587. PubMed ID: 22412892 [TBL] [Abstract][Full Text] [Related]
35. "I would have to sell things in order to get the money": A qualitative exploration of willingness to pay for the RTS,S/AS01 malaria vaccine in the Volta region, Ghana. Darkwa S; de Wildt G; Dalaba M; Vidzro E; Ansah EK PLoS One; 2022; 17(6):e0268009. PubMed ID: 35675273 [TBL] [Abstract][Full Text] [Related]
37. The role of different components of the immune system against Plasmodium falciparum malaria: Possible contribution towards malaria vaccine development. Mandala WL; Harawa V; Dzinjalamala F; Tembo D Mol Biochem Parasitol; 2021 Nov; 246():111425. PubMed ID: 34666102 [TBL] [Abstract][Full Text] [Related]
38. Prioritizing the scale-up of interventions for malaria control and elimination. Winskill P; Walker PG; Cibulskis RE; Ghani AC Malar J; 2019 Apr; 18(1):122. PubMed ID: 30961603 [TBL] [Abstract][Full Text] [Related]
39. Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation. Osoro CB; Ochodo E; Kwambai TK; Otieno JA; Were L; Sagam CK; Owino EJ; Kariuki S; Ter Kuile FO; Hill J BMJ Glob Health; 2024 Apr; 9(4):. PubMed ID: 38688566 [TBL] [Abstract][Full Text] [Related]
40. Modelling the cost-effectiveness of mass screening and treatment for reducing Plasmodium falciparum malaria burden. Crowell V; Briët OJ; Hardy D; Chitnis N; Maire N; Di Pasquale A; Smith TA Malar J; 2013 Jan; 12():4. PubMed ID: 23286228 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]